CL2023002704A1 - Inhibidores heterocíclicos de la cinasa rip1 - Google Patents

Inhibidores heterocíclicos de la cinasa rip1

Info

Publication number
CL2023002704A1
CL2023002704A1 CL2023002704A CL2023002704A CL2023002704A1 CL 2023002704 A1 CL2023002704 A1 CL 2023002704A1 CL 2023002704 A CL2023002704 A CL 2023002704A CL 2023002704 A CL2023002704 A CL 2023002704A CL 2023002704 A1 CL2023002704 A1 CL 2023002704A1
Authority
CL
Chile
Prior art keywords
heterocyclic
kinase inhibitors
rip1 kinase
inhibitor compounds
rip1
Prior art date
Application number
CL2023002704A
Other languages
English (en)
Inventor
Vanessa Taylor
Simon Shaw
Somasekhar Bhamidipati
Kyle Defrees
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CL2023002704A1 publication Critical patent/CL2023002704A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente descripción se describen compuestos inhibidores de cinasa, tales como compuestos inhibidores de proteína 1 cinasa que interactúa con el receptor (RIP1), de la Fórmula (I), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas, y/o combinaciones descritas pueden usarse para tratar o prevenir una enfermedad o afección asociada a cinasas, particularmente una enfermedad o afección asociada a RIP 1.
CL2023002704A 2021-03-11 2023-09-11 Inhibidores heterocíclicos de la cinasa rip1 CL2023002704A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163159970P 2021-03-11 2021-03-11

Publications (1)

Publication Number Publication Date
CL2023002704A1 true CL2023002704A1 (es) 2024-03-22

Family

ID=81327717

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002704A CL2023002704A1 (es) 2021-03-11 2023-09-11 Inhibidores heterocíclicos de la cinasa rip1

Country Status (18)

Country Link
US (1) US20220296608A1 (es)
EP (1) EP4304713A1 (es)
JP (1) JP2024509466A (es)
KR (1) KR20230144575A (es)
CN (1) CN117083270A (es)
AR (1) AR125587A1 (es)
AU (1) AU2022232927A1 (es)
BR (1) BR112023018167A2 (es)
CA (1) CA3211778A1 (es)
CL (1) CL2023002704A1 (es)
CO (1) CO2023012077A2 (es)
CR (1) CR20230438A (es)
DO (1) DOP2023000186A (es)
EC (1) ECSP23068893A (es)
IL (1) IL305456A (es)
PE (1) PE20240237A1 (es)
TW (1) TW202300490A (es)
WO (1) WO2022192533A1 (es)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
IE66203B1 (en) 1989-12-04 1995-12-13 Searle & Co System for transdermal albuterol administration
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ マイニング アンド マニュファクチャリング カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US8922322B2 (en) * 2012-08-31 2014-12-30 Delta Electronics, Inc. Combined structure of hollow bobbin and conductive sheet, hollow bobbin, and conductive sheet
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US20170266199A1 (en) * 2014-08-21 2017-09-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
MY192762A (en) * 2015-07-02 2022-09-07 Hoffmann La Roche Bicyclic lactams and methods of use thereof
CN109071504B (zh) * 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
JP7045526B2 (ja) * 2018-11-02 2022-03-31 中国科学院上海薬物研究所 Rip1キナーゼを阻害する複素環状アミド及びその使用
CA3149963A1 (en) * 2019-09-06 2021-03-11 Simon Shaw Heterocyclic rip1 kinase inhibitors
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica

Also Published As

Publication number Publication date
ECSP23068893A (es) 2023-10-31
CA3211778A1 (en) 2022-09-15
AR125587A1 (es) 2023-08-02
DOP2023000186A (es) 2023-11-30
BR112023018167A2 (pt) 2023-10-31
PE20240237A1 (es) 2024-02-16
AU2022232927A1 (en) 2023-08-17
WO2022192533A1 (en) 2022-09-15
CN117083270A (zh) 2023-11-17
CR20230438A (es) 2024-01-16
US20220296608A1 (en) 2022-09-22
KR20230144575A (ko) 2023-10-16
JP2024509466A (ja) 2024-03-01
TW202300490A (zh) 2023-01-01
EP4304713A1 (en) 2024-01-17
CO2023012077A2 (es) 2024-01-15
IL305456A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
DOP2022000051A (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
CL2022002695A1 (es) Inhibidores de rip1k
DOP2023000169A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
ECSP20077518A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
DOP2022000042A (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
DOP2018000241A (es) Derivados aromáticos de sulfonamida
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CL2022003812A1 (es) Inhibidores de rip1k
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
CO2023012077A2 (es) Inhibidores heterocíclicos de la cinasa rip1
ECSP22083926A (es) Compuestos útiles para inhibir la quinasa ret
AR120412A1 (es) Compuestos heterocíclicos inhibidores de rip1
UY38133A (es) Nuevos inhibidores de cdk8/19
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
CU20200020A7 (es) Composición farmacéutica que comprende abx196